No profile data available.
Century Therapeutics, Inc. (IPSC) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Philadelphia, United States, with about 78 full-time employees.
It reported revenue of $109.16 million for fiscal year 2025, up 1556.8% from fiscal year 2024, and net income of -$9.58 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $266.18 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. 0 for the treatment of type 1 diabetes. 0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc.
Century Therapeutics reported $109.16 million in revenue for fiscal year 2025, up 1556.8% from $6.59 million in fiscal year 2024. In Q2 2026 revenue was $0.
$266.18 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Kyverna Therapeutics, Inc. (KYTX), Zura Bio Limited (ZURA), Cabaletta Bio, Inc. (CABA), Cue Biopharma, Inc. (CUE).